Premium
Finasteride induces Epigenetic Modulation of LSP1: A Gene implicated in Neutrophil Actin Dysfunction disease
Author(s) -
Ihentuge Churchill,
Csoka Antonei
Publication year - 2022
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2022.36.s1.r4708
Subject(s) - epigenetics , dna methylation , biology , methylation , inflammation , cancer research , gene expression , gene , microbiology and biotechnology , immunology , genetics
Lymphocyte Specific Protein 1 (LSP1) gene translates F‐actin protein expressed in leucocytes such as neutrophils, lymphocytes, macrophages, and endothelium. It controls neutrophil motility, adhesion to fibrinogen matrix proteins, and transendothelial migration. Overexpression or increased level of Lymphocyte Specific Protein 1 (LSP1) is implicated in a rare immunologic disorder Neutrophil Actin Dysfunction characterized by spontaneous onset of recurrent infections and inflammation of oral cavity, skin, and respiratory tract. In this experiment aimed at studying the methylation profile and genes expression following finasteride treatment, we cultured human Leydig cells in the presence of 0.5 μM finasteride for 14 days and performed whole‐genome DNA methylation analysis using the NimbleGen Human DNA Methylation 3×720K Promoter Plus CpG Island Array and Ingenuity Pathway Analysis. Results identified several genes that were differentially methylated following finasteride treatment. Lymphocyte Specific Protein 1 (LSP1) gene was downregulated through methylation. We therefore deduced that finasteride could be a gateway to the treatment of Neutrophil Actin Dysfunction disease through epigenetic modification and decreased expression of LSP1 gene.